allogeneic CAR-iNK cell therapy (Tome Biosciences)

N/A

Report date: 2025/06/11 11:02:27

Base Information

Drug Nameallogeneic CAR-iNK cell therapy (Tome Biosciences)
Drug Alias Namedual anti-CD19/anti-BCMA-CAR-iNK allogeneic cell therapy (Tome Biosciences)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsNatural killer cells stimulantsTumor necrosis factor ligand superfamily member 13 modulators
TargetsB-lymphocyte antigen CD19Tumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsAutoimmune DiseasesNephrosis, LipoidLupus Nephritis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTome Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesTome Biosciences Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNephrosis, LipoidLupus Nephritis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A